Key indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.004 Å; R factor = 0.046; wR factor = 0.118; data-to-parameter ratio = 13.3.
Related literature
The pyrazolo [3,4-b] pyridine system represents the core skeleton of a pharmaceutically important class of heterocyclic compounds that possess a broad range of biological activity, see: Beutner et al. (2009) ; Hamblin et al. (2008) ; Jiang et al. (2011) ; Lynck et al. (1988) ; Manetti et al. (2005) ; Meiners & Salama (1982) ; Revesz et al. (2006) ; Witherington et al. (2003) . For related structures, see: Chebanov et al. (2007) ; Lee & Park (2009) ; Quiroga et al. (2001) .
Experimental
Crystal data C 22 H 18 ClN 3 S M r = 391.90 Monoclinic, P2 1 =c a = 8.8731 (9) Å b = 19.9044 (18) Å c = 10.5292 (11) Å = 96.689 (1) V = 1846.9 (3) Å 3 Z = 4 Mo K radiation = 0.33 mm À1 T = 298 K 0.48 Â 0.19 Â 0.18 mm
Data collection
Bruker SMART CCD area-detector diffractometer Absorption correction: multi-scan (SADABS; Sheldrick, 1996) T min = 0.857, T max = 0.943 9193 measured reflections 3264 independent reflections 1988 reflections with I > 2(I) R int = 0.049 Refinement R[F 2 > 2(F 2 )] = 0.046 wR(F 2 ) = 0.118 S = 1.02 3264 reflections 245 parameters H-atom parameters constrained Á max = 0.24 e Å À3 Á min = À0.32 e Å À3 Table 1 Hydrogen-bond geometry (Å , ).
Please define Cg1 is the centroid of the C17-C22 ring.
Symmetry codes: (i) Àx þ 1; Ày þ 1; Àz þ 2; (ii) Àx þ 2; Ày þ 1; Àz þ 1.
Data collection: SMART (Bruker, 1998) ; cell refinement: SAINT (Bruker, 1999) ; data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL. -methyl-3-phenyl-3,6,8,9-tetrahydropyrazolo[3,4-b] 
5-(4-Chlorophenyl)-1
R. Jia and J. Peng
Comment
The pyrazolo [3,4-b] pyridine system as a key heterocycle represents the core skeleton of a pharmaceutically important class of heterocyclic compounds that possess a broad range of biological activities (Beutner et al., 2009) , such as anxiolytic activity (Meiners et al., 1982) , and can be used in the inhibition of xanthine oxidases (Lynck et al., 1988) , cholesterol formation and in the treatment of Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction and infertility. They have also been reported as potent and selective inhibitors of A1 adenosine receptors (Manetti et al., 2005) , phosphodiesterase 4 (PDE4) inhibitors in immune and inflammatory cells (Hamblin et al. 2008) , glycogen synthase kinase-3 (GSK-3) inhibitors (Witherington et al., 2003) and kinase inhibitors of p38 as anti-inflammatory drugs (Revesz et al., 2006) . Because of the biological activities they exhibit, these compounds have distinguished themselves as heterocycles of profound chemical and biological significance.
Thus, the preparation of these molecules has attracted considerable attention (Lee et al., 2009 ). Many pyrazolo [3,4b] pyridines have been synthesized through the reactions of 5-aminopyrazoles, aldehydes and appropriate cycloketones by various methods (Quiroga et al. 2001) . However, most of these compounds are pyrazolo [3,4-b] pyridines with the aryl group at the 4-position of the pyridine ring. Recently, Chebanov and co-workers synthesized unexpected pyrazolopyridines by similar three-component reactions under strong basic conditions (Chebanov et al., 2007) . In this reaction, the aryl group was also located at the 4-position of the pyridine ring. Recently, Jiang et al. (Jiang et al., 2011) have reported a facile one-pot reaction for the synthesis of the regioselective construction of macrocyclane-fused pyrazolo [3,4-b] pyridines with an aryl group at the 2-position of the pyridine nucleus.
In this paper we report the crystal structure of the title compound, C 22 H 18 ClN 3 S, which was synthesized by the reaction of 4-chlorobenzaldehyde, tetrahydrothiopyran-4-one, and 3-methyl-1-phenyl-1H-pyrazol-5-amine in acetic acid without catalyst.
In the crystal structure, the pyridine and pyrazole rings are almost coplanar. Indeed, the dihedral angle between the pyridine C1/C2/C7/C6/C10/N1 plane and the C1/C2/C3/N3/N2 pyrazole ring is 2.50 (1)°. The thiopyran ring exhibits an envelope conformation. The molecules are connected via C-H···Cl hydrogen bonds and C-H···π interactions ( Fig. 2 ; Table 1 ). Furthermore, intermolecular π-π interactions between two parallel neighboring pyridine rings are observed. The centroid-centroid distance and the perpendicular distance of the centroid on the neighboring ring are 3.825 (2) and 3.472 (1).
Even shorter interactions exist between the pyrazole and pyridine rings with corresponding distances of 3.557 (2) and 3.516 (1) Å, respectively. supplementary materials sup-2
Experimental
The title compound was prepared by the reaction of 4-chlorobenzaldehyde (1 mmol), tetrahydrothiopyran-4-one (1 mmol) and 3-methyl-1-phenyl-1H-pyrazol-5-amine (1 mmol) in acetic acid (2.0 ml). Single crystals suitable for X-ray diffraction were obtained by slow evaporation of a 95% aqueous ethanol solution (yield 89%; m.p. 473-475 K).
IR (cm -1 ): 3068, 2963, 2896, 1592, 1577, 1506, 1415, 1383, 1286, 1104, 1090, 1014, 911, 8839, 756, 693. 1 
Refinement
All H atoms were positioned geometrically and treated as riding, with C-H = 0.93 Å and U iso (H) = 1.2U eq (C) for aromatic H atoms, with C-H = 0.97 Å and U iso (H) = 1.2U eq (C) for methylene H atoms, and with C-H = 0.96 Å and U iso (H) = 1.5U eq (C) for methyl H atoms.
In the hydrogen-bond geometry table, Cg1 corresponds to the centroid of the C17/C18/C19/C20/C21/C22 ring. 5-(4-Chlorophenyl)-1-methyl-3-phenyl-3, 6,8,9-tetrahydropyrazolo[3,4-b] 
